Zopiclone is a prescription sedative-hypnotic used to treat insomnia, belonging to a class commonly called “Z-drugs” alongside zolpidem and zaleplon. Although it is chemically unrelated to benzodiazepines, it acts on the same brain receptor system, and that overlap shapes much of what matters about the drug: its effectiveness, its side effects, its dependence potential, and even how an overdose is reversed. Widely prescribed across Europe, Canada, Australia, and parts of Asia and Latin America, zopiclone occupies an unusual position in global medicine because it has never been approved by the FDA for use in the United States, where a modified version called eszopiclone is available instead.
How Zopiclone Works
Zopiclone belongs to the cyclopyrrolone chemical family, which means its molecular structure looks nothing like a benzodiazepine under the microscope. But the two drugs arrive at the same destination. Zopiclone acts on the GABA-A receptor complex, the brain’s primary “calm down” switch, by working at a site that is distinct from but closely related to where benzodiazepines bind.1PubMed. Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic The practical result is the same: the drug amplifies the effects of GABA, the neurotransmitter that quiets nerve activity, making it easier to fall asleep and stay asleep.2PubMed. The mechanism of action of zopiclone
This shared receptor target is why zopiclone behaves so much like a benzodiazepine in practice, from sedation and muscle relaxation to the risk of dependence. The distinction between the two drug families matters more to chemists than to your body.
The Eszopiclone Connection
Zopiclone is actually a 50/50 mixture of two mirror-image molecules, called enantiomers. Only one of those mirror images, the S-isomer, produces sedation. The R-isomer has no sleep-promoting activity at all.3PubMed Central. Eszopiclone: its use in the treatment of insomnia Pharmaceutical companies isolated the active S-isomer and marketed it as eszopiclone (brand name Lunesta) in the United States, where it received FDA approval in 2004. In countries where zopiclone itself is prescribed, you are essentially taking the active half along with a pharmacologically inert companion molecule. This is why a standard zopiclone dose of 7.5 mg is roughly comparable to a 3 mg dose of eszopiclone: you need more of the racemic mixture to get the same amount of the active ingredient.
Zopiclone has never been approved by the FDA for marketing in the U.S.4PLoS One. Suicide adverse events associated with zopiclone and eszopiclone: A pharmacovigilance analysis based on FAERS, JADER and CVARD If you are in the U.S. and your doctor prescribes a cyclopyrrolone sleep aid, it will be eszopiclone. Zopiclone has been available in Europe, Canada, and Latin America since 1987.5PubMed Central. Eszopiclone: its use in the treatment of insomnia
What It Does for Sleep
At the standard 7.5 mg dose, zopiclone shortens the time it takes to fall asleep, reduces how long you spend awake after initially dozing off, and increases total sleep time.6PubMed. A sleep laboratory evaluation of the long-term efficacy of zopiclone These effects have been measured in sleep-lab studies where brain activity is tracked throughout the night, so the improvements are not just people feeling like they slept better. Lower doses work too: even 5 mg increases total sleep time and shortens the time to fall asleep compared to placebo, though doses below that do not seem to do much.7Human Psychopharmacology: Clinical and Experimental. The dose effects of zopiclone
One area where zopiclone genuinely differs from older benzodiazepine sleeping pills is sleep architecture. Benzodiazepines tend to suppress REM sleep (the dreaming stage) and reduce deep slow-wave sleep, which is the most restorative phase. Zopiclone leaves REM sleep largely intact and either preserves or even increases slow-wave sleep.8PubMed. Zopiclone, the third generation hypnotic: a clinical overview In other words, you are not just sleeping longer; the structure of that sleep looks more like natural sleep than what older sedatives produce. This was one of the original selling points when zopiclone was introduced as a so-called “third generation” hypnotic.
The Metallic Taste and Other Side Effects
If there is one side effect that nearly every zopiclone user knows, it is the bitter or metallic taste that appears shortly after taking the pill and often lingers into the following morning. This happens because the drug is secreted into saliva after absorption, and when it reaches taste buds and oral mucosal receptors directly, it triggers a localized taste disturbance.9PubMed Central. Detection of Signals for Smell and Taste Disorders Associated with Z-drugs: A Disproportionality Analysis of the FAERS Database The taste is distinctive enough that many users describe it as the drug’s most recognizable signature. It is usually harmless but can be unpleasant enough to affect adherence, and it tends to be more pronounced with zopiclone than with other Z-drugs.
Headache is another side effect that shows up more often with zopiclone than with placebo. A meta-analysis looking at Z-drugs and newer alternatives found the probability of zopiclone causing a headache was roughly four times higher than placebo.10PubMed Central. Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis Dry mouth, daytime drowsiness, and dizziness are also commonly reported.
Next-Day Impairment and Driving Risk
This is the side effect that arguably matters most for everyday safety. Zopiclone has a half-life of about five hours, which sounds short enough that it should be out of your system by morning. But “half-life” means only half the drug is eliminated in that window, and enough active compound remains the next day to measurably affect driving, memory, and coordination.
In an on-the-road driving study, people who took 7.5 mg of zopiclone the night before showed significant increases in lane weaving the following morning, a standard measure of driving impairment. The effect was seen in both people with insomnia and healthy volunteers.11PubMed Central. Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study Beyond lane weaving, zopiclone impaired memory recall, psychomotor tracking, reaction time, and balance the next morning.12Sleep. Next-Day Effects of Ramelteon (8 mg), Zopiclone (7.5 mg), and Placebo on Highway Driving Performance, Memory Functioning, Psychomotor Performance, and Mood in Healthy Adult Subjects
Across the broader literature, patients taking zopiclone have over double the risk of motor vehicle collisions compared to unexposed drivers.13PubMed Central. In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving This is not a subtle laboratory finding; it translates to real crashes. It also means that the common assumption “Z-drugs are safer than benzodiazepines for next-day function” is not uniformly true. Zopiclone and higher doses of zolpidem are the Z-drugs most likely to cause anterograde amnesia and residual impairment the following day.14PubMed Central. In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving If you take zopiclone, planning for at least eight or nine hours of sleep before you need to drive is not just good advice; in several countries, it is reflected in official prescribing guidance.
Sleepwalking and Complex Sleep Behaviors
One of the stranger risks with Z-drugs is that they can trigger behaviors during sleep that the person has no memory of afterward. In a study of over 1,200 users of zopiclone or zolpidem, about 3% reported incidents of sleepwalking or amnesic sleep-related behaviors. These included eating food during the night without remembering, walking around the house, and carrying on conversations, all while technically asleep.15PubMed Central. A comparison of complex sleep behaviors with two short-acting Z-hypnosedative drugs in nonpsychotic patients Sleep-eating and sleep-driving have both been documented, though driving during a zopiclone-induced fugue is rare. The total amnesia for the event is what makes these behaviors particularly unsettling for users and their families.
Dependence, Tolerance, and Withdrawal
Zopiclone was originally marketed with the promise that it carried less dependence risk than benzodiazepines. The reality is more nuanced. In short-term clinical trials lasting four weeks or less, tolerance to zopiclone’s sleep-promoting effects was not observed, and the drug maintained its effectiveness with continued use.16PubMed. A sleep laboratory evaluation of the long-term efficacy of zopiclone But the picture gets murkier beyond that timeframe: longer-term data on tolerance are conflicting, and researchers have not been able to clearly establish whether the drug stays effective over months of nightly use.17PubMed. Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia
Physical dependence does occur, although less frequently than with benzodiazepines. What caught prescribers off guard is that dependence can develop even in people with no prior history of substance misuse, sometimes in as little as two months of regular use.18Prescriber Update. Zopiclone Dependence Rebound insomnia, where sleep briefly becomes worse than before the drug was started, can happen when zopiclone is stopped abruptly, although short-term studies suggest this is uncommon.19PubMed. Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia Most prescribing guidelines now recommend limiting treatment to four weeks or less, and if use has continued longer, a gradual taper rather than abrupt cessation.20Prescriber Update. Zopiclone Dependence
Who Is Most at Risk of Misuse
Population-level monitoring suggests zopiclone does not have a high dependence potential in the general prescribing population.21PubMed. Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia But when misuse does develop, it follows a pattern. The people most likely to escalate doses or become dependent typically have a pre-existing history of substance abuse or an underlying psychiatric illness.22PubMed. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data Case reports of zopiclone abuse often follow a trajectory where the drug was started at the standard 7.5 mg dose and gradually climbed from there, sometimes to very high daily amounts.23PubMed Central. Zopiclone: Is it a pharmacologic agent for abuse?
None of this means zopiclone is universally “safe” for people without addiction histories, as the New Zealand experience showed. But it does suggest that prescribers should be especially cautious when patients have risk factors for substance misuse and should monitor any patient whose dose starts creeping upward.
Zopiclone in Older Adults
Insomnia becomes more common with age, and so does zopiclone prescribing, but this is a population where the drug’s risks are amplified. A large population-based study found that zopiclone users had about a 36% higher risk of fractures compared to non-users, after adjusting for other medications that could contribute to falls. That risk climbed steadily with age.24PubMed. Zopiclone Use and Risk of Fractures in Older People: Population-Based Study
The hip fracture risk is even more striking. A case-control study in Taiwan found that current zopiclone users were roughly three and a half times as likely to experience a hip fracture compared to non-users.25PubMed. Correlation Between Use of Zopiclone and Risk of Hip Fracture in Elderly Adults: A Case-Control Study in Taiwan Hip fractures in older people are not minor events; they carry significant mortality risk and are a leading cause of loss of independence. The combination of next-day sedation, impaired balance, and nocturnal confusion makes the mechanism straightforward: sedated older people fall, and falls break bones. This is why most geriatric prescribing guidelines classify zopiclone, along with other Z-drugs and benzodiazepines, as potentially inappropriate for older adults except in short-term, carefully monitored situations.
Overdose and Reversal
Because zopiclone acts on GABA receptors that overlap with benzodiazepine binding sites, flumazenil, the standard benzodiazepine antidote, can reverse zopiclone overdose. That said, most zopiclone overdoses are managed with supportive care alone, and flumazenil carries its own risks, including the potential to trigger seizures in people who are physically dependent.26PubMed Central. Zopiclone overdose and flumazenil rescue Zopiclone taken alone in overdose is generally less lethal than many older sedatives, but it becomes much more dangerous when mixed with alcohol, opioids, or other central nervous system depressants.
How Zopiclone Compares to Behavioral Treatment
The strongest evidence for treating chronic insomnia without drugs comes from cognitive behavioral therapy for insomnia, known as CBT-I, which uses techniques like sleep restriction, stimulus control, and cognitive restructuring to retrain sleep habits. A randomized trial compared six weeks of CBT-I against six weeks of nightly zopiclone (7.5 mg) in older adults with chronic insomnia, then followed everyone for six months.
At the six-month mark, the CBT group had improved their sleep efficiency from about 81% at the start to 90%, while the zopiclone group had essentially returned to baseline, going from 82% to 82%.27JAMA. Cognitive Behavioral Therapy vs Zopiclone for Treatment of Chronic Primary Insomnia in Older Adults: A Randomized Controlled Trial Total time spent awake during the night dropped by about half in the CBT group after six weeks, compared to a negligible change with zopiclone. And by six months, nearly 80% of CBT participants had sleep efficiency above 85%, compared to 40% of those who had taken zopiclone.28JAMA. Cognitive Behavioral Therapy vs Zopiclone for Treatment of Chronic Primary Insomnia in Older Adults: A Randomized Controlled Trial
This does not mean zopiclone is useless. It works quickly, which matters when someone is in acute distress from sleeplessness. But for chronic insomnia, the pattern is consistent: the drug helps while you take it, and the benefits fade when you stop. Behavioral treatment takes longer to kick in but produces durable improvement that persists after therapy ends. Most current clinical guidelines recommend CBT-I as the first-line treatment for chronic insomnia in adults, with medications like zopiclone reserved for short-term use or situations where behavioral therapy is unavailable or has failed.
Zopiclone in Pregnancy and Breastfeeding
Data on zopiclone use during pregnancy are limited, and the drug is generally not recommended for pregnant women due to insufficient safety evidence. For breastfeeding, the pharmacokinetic data are more specific. A study measuring zopiclone levels in breast milk found that the milk-to-plasma ratio was about 0.51, meaning the drug does pass into breast milk but at roughly half the concentration found in the mother’s blood. The estimated dose reaching an infant through breast milk would be about 1.4% of the mother’s weight-adjusted dose.29PubMed Central. The excretion of zopiclone into breast milk That is a low exposure level, but because newborns metabolize drugs more slowly than adults, any sedative exposure in infants warrants caution. Occasional one-off use might be considered in some clinical situations, but regular use while breastfeeding is generally advised against.
Zopiclone in Forensic Investigations
Zopiclone’s rapid onset and short duration of action, combined with its ability to cause amnesia, have made it a drug of concern in forensic toxicology, particularly in cases of suspected drug-facilitated crimes. Because the drug is eliminated from blood and urine relatively quickly, standard testing can miss it if the sample is not collected soon after exposure. Hair analysis has emerged as an alternative way to detect zopiclone exposure weeks or even months after the fact.
Forensic labs have validated methods to detect zopiclone and its main metabolites in blood, urine, and hair samples simultaneously.30Journal of Analytical Toxicology. Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of 26 Benzodiazepines and Metabolites, Zolpidem and Zopiclone, in Blood, Urine, and Hair Hair analysis is especially useful because it can distinguish between a single exposure and repeated use. In one documented criminal case, a single exposure produced hair concentrations around 4 pg/mg in the corresponding hair segment, while a case involving repeated administration showed concentrations about five times higher.31PubMed. Testing for zopiclone in hair application to drug-facilitated crimes Researchers have also worked to establish reference values by administering single doses to volunteers and then tracking how the drug and its metabolites incorporate into growing hair, building a baseline that forensic experts can use for interpretation.32PubMed. Distribution of zopiclone and main metabolites in hair following a single dose
The existence of this forensic toolbox matters for two reasons. For law enforcement, it means that zopiclone administration can sometimes be proven long after the drug has cleared from blood. For prescribers and patients, it is a reminder that the same pharmacological properties that make zopiclone effective as a sleep aid, its rapid sedation and capacity for amnesia, also create risks that extend beyond the clinical setting.